| ¼Ò¾Æ¿¡¼ÀÇ ÀÌ»óÁöÁúÇ÷Áõ (Dyslipidemia in children) |
|
| ÀÎÁ¦ÀÇ´ë »ó°è¹éº´¿ø ¼Ò¾ÆÃ»¼Ò³â°ú ¹Ú ¹Ì Á¤ |
|
 |
ÃÖ±Ù, ¼Ò¾Æ û¼Ò³âÀÇ ºñ¸¸ÀÌ ±ÞÁõÇϰí ÀÖ¾î ÀÌ¿¡ µû¸¥ ÀÌ»óÁöÁúÇ÷ÁõÀÇ À¯º´À²µµ ³ôÀ» °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ¼Ò¾ÆÃ»¼Ò³âÀÇ ÁöÁú³óµµ ±âÁØÀ̳ª ü°èÈµÈ Ä¡·á ±Ç°í¾ÈÀº µå¹°´Ù.
1. ÀÌ»óÁöÁúÇ÷ÁõÀÇ ¿øÀÎ 1Â÷¼º °íÁöÁúÇ÷ÁõÀÇ °¡Àå ÈçÇÑ ¿øÀÎÀº °¡Á·¼º °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ(familial hypercholesterolemia) À̸ç LDL ¼ö¿ëüÀÇ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇÑ´Ù. 2Â÷¼º ÀÌ»óÁöÁúÇ÷ÁõÀÇ ¿øÀÎÀº °©»ó»ùÀúÇÏÁõ, ´ç´¢º´, ½ÅÁõÈıº, À½ÁÖ, Èí¿¬, ½ºÆ®·¹½º, °£¿°, Äí½ÌÁõÈıº, ½ºÅ×·ÎÀ̵å, ¿¡½ºÆ®·Î°Õ, thiazide, ¥â blocker µîÀÌ ÀÖÀ¸¸ç, ƯÈ÷ ºñ¸¸¿¡ ÀÇÇÑ |
ÀÌ»óÁöÁúÇ÷ÁõÀÌ ÈçÇÏ´Ù. ºñ¸¸ÀÎ °æ¿ì Àν¶¸° ÀúÇ×¼ºÀ¸·Î ÀÎÇØ °íÀν¶¸°Ç÷Áõ»óŰ¡ µÇ¸é Áö¹æ ºÐÇØÀÇ Áõ°¡·Î °£ ³» À¯¸®Áö¹æ»ê( Free Fatty Acid)ÀÇ À¯ÀÔÀÌ Áõ°¡µÇ°í, °£À¸·Î °¡¼ Áß¼ºÁö¹æ(TG) »ý¼ºÀÇ ¿ø·á°¡ µÈ´Ù. °£¿¡¼ TG »ý¼ºÀÌ Áõ°¡µÇ¾î TG¸¦ °¡Àå ¸¹ÀÌ Æ÷ÇÔÇÑ ÃÊÀú¹ÐµµÁö´Ü¹é (very low density lipoprotein:VLDL)ÀÌ Áõ°¡µÇ¸ç apoBÀÇ ºÐÇØ´Â °¨¼ÒµÈ´Ù. Ç÷Áß Áõ°¡µÈ TG¸¦ ´ë»çÇϱâ À§ÇØ Cholesterol ester transfer protein(CETP, cholesterol°ú TG¸¦ 1:1 ·Î ±³È¯ÇÏ´Â ¿ªÇÒ)¶ó´Â È¿¼Ò°¡ Ȱ¼ºÈ µÇ¾î °úµµÇÑ Áß¼ºÁö¹æÀ» LDL, HDL ÀÔÀÚ·Î Àü´ÞÇÑ´Ù. TG°¡ ¸¹Àº HDLÀº hepatic lipase¿¡ ÀÇÇØ ±Þ¼ÓÈ÷ ´ë»çµÇ°í Å©±â°¡ ÀÛ¾ÆÁø HDL·Î µÇ¾î ½ÅÀåÀ¸·Î ¹è¼³µÇ¸ç HDLÀ» ±¸¼ºÇÏ´Â ´Ü¹éÁúÀÎ apoprotein A-1ÀÇ ¼Ò¸ðÀ²ÀÌ Áõ°¡µÇ¾î Ç÷Áß HDL ÄÝ·¹½ºÅ×·ÑÀº °¨¼ÒÇÑ´Ù. TG°¡ ¸¹Àº LDL¿ª½Ã hepatic lipaseÀÇÇØ ÀÔÀÚÀÇ Å©±â°¡ °¨¼ÒµÇ°í, ¹Ðµµ°¡ Áõ°¡µÈ small dense LDL ·Î º¯ÈµÇ¸é ½±°Ô »êȵǰí, ¼ö¿ëü¿¡ ÀÇÇÑ Á¦°ÅÀÛ¿ëÀÌ ¶³¾îÁö¸ç, Ç÷°üº®¿¡ Àß Ä§ÂøµÇ°í, ¿°Áõ¹ÝÀÀ°ú Á׻󵿸ưæÈÁõ ¹× ½ÉÇ÷°üÁúȯÀÇ À§Çè¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°Ô µÈ´Ù.
2. ¼Ò¾ÆÀÇ ÁöÁú°Ë»ç °ËÁø ´ë»ó ¸¸ 2¼¼°¡ Áö³ÈÄ ´ÙÀ½°ú °°Àº À§Çè¿ä¼Ò°¡ ÀÖ´Â °æ¿ì ½ÃÇàÇÑ´Ù. ¨ç ºÎ¸ðÁß ÇÑ»ç¶÷ÀÇ ÃÑ ÄÝ·¹½ºÅ×·Ñ³óµµ >240mg/dL ¨è. Á÷°è°¡Á·³» Á¶±â (³²<55, ¿©<65¼¼) ½ÉÇ÷°ü Áúȯ ¨é ¼Ò¾Æ°¡ ´ÙÀ½ÀÇ À§ÇèÀÎÀÚ¸¦ °¡Áø °æ¿ì; ºñ¸¸, Èí¿¬, °íÇ÷¾Ð, ´ç´¢º´, ¿òÁ÷ÀÌÁö ¸øÇÏ´Â »óÅÂ, ½ÅÀåÁúȯ, ´ãµµ°ü Áúȯ, °©»ó¼±Áúȯ, Äí½ÌÁõÈıº, ½ºÅ×·ÎÀ̵å Àå±â°£ »ç¿ë)
3. ¼Ò¾ÆÀÇ ÀÌ»óÁöÁúÇ÷Áõ ±âÁØ ¨ç ÃÑ ÄÝ·¹½ºÅ×·Ñ ¡Ã 200 mg/dL, ¨è LDL ÄÝ·¹½ºÅ×·Ñ ¡Ã130 mg/L, ¨é HDL ÄÝ·¹½ºÅ×·Ñ <40-45 mg/dL, ¨ê Áß¼ºÁö¹æ: û¼Ò³â ¡Ã150 mg/dL,, ¼Ò¾Æ¡Ã130 mg/dL
¼Ò¾ÆÃ»¼Ò³âÀÇ ÁöÁú, Áö´Ü¹é ³óµµ
|
|
AcceptableM |
Borderline |
High |
Low |
| Total Cholesterol |
<170 |
170-199 |
¡Ã200 |
|
| LDL- Cholesterol |
<110 |
110-129 |
¡Ã130 |
|
| Non HDL- Cholesterol |
<123 |
123-143 |
¡Ã144 |
|
| ApoB |
<90 |
90-109 |
¡Ã110 |
|
| Triglyceride |
|
|
|
|
| 0-9y |
<75 |
75-99 |
¡Ã100 |
|
| 10-19y |
<90 |
90-129 |
¡Ã130 |
|
| HDL- Cholesterol |
45 |
35-45 |
|
<35 |
| ApoA1 |
>120 |
110-120 |
|
<110 |
| (from the National Cholesterol Education Program (NCEP) Expert Panel on Cholesterol Levels in Children , National Health and Nutrition Examination Survey III data)
4. ÀÌ»óÁöÁúÇ÷Áõ ȯ¾ÆÀÇ ½Ä»ç°ü¸® ¨ç ¸ñÇ¥: LDL ÄÝ·¹½ºÅ×·Ñ <110mg/dL Step1: Áö¹æ¼·Ãë :ÃÑÄ®·Î¸®ÀÇ 30% ¹Ì¸¸ Æ÷ÈÁö¹æ¼·Ãë: 10% ¹Ì¸¸ ÄÝ·¹½ºÅ×·Ñ : 300mg ¹Ì¸¸ ( ź 55%, ´Ü 15-20%) ¡é (step1 À¸·Î 3°³¿ù ÈÄ ¸ñÇ¥´Þ¼º ¾ÈµÇ¸é) Step 2: Áö¹æ¼·Ãë :ÃÑÄ®·Î¸®ÀÇ 30% ¹Ì¸¸ Æ÷ÈÁö¹æ¼·Ãë: 7~8% ¹Ì¸¸ ÄÝ·¹½ºÅ×·Ñ : 200mg ¹Ì¸¸ ¨è.±âŸ ¼¶À¯¼Ò, Fish oil , Ç×»êÈÁ¦ ¼·Ã븦 Áõ°¡½ÃŲ´Ù.
5. ÀÌ»óÁöÁúÇ÷Áõ ȯ¾ÆÀÇ ¾à¹°Ä¡·á 10¼¼ ÀÌ»óÀ̰í 6°³¿ù Á¤µµ ½ÄÀÌ¿ä¹ý ÈÄ¿¡µµ ¨ç LDL>190mg/dl ȤÀº ¨è. LDLÀÌ 160-189mg/dÀ̰í + Á¶±â ½ÉÇ÷°üÁúȯ °¡Á··Â ¨é. LDLÀÌ 160-189mg/dÀ̰í + 2°³ÀÌ»óÀÇ ½ÉÇ÷°üÁúȯ À§ÇèÀÎÀÚ (2Çü´ç´¢º´,°íÇ÷¾Ð,Èí¿¬,ºñ¸¸(ÀÌ»óüÁß>30%),HDL<35gm/dl)ÀÌ ÀÖ´Â °æ¿ì ¾à¹°Ä¡·á¸¦ °í·ÁÇÑ´Ù.
°ú°Å¿¡´Â ¼Ò¾Æ °íÁöÇ÷ÁõÀÇ 1Â÷ ¼±ÅþàÀº ´ãÁó»ê ¼öÁö(Bile acid sequestrants)¿´´Ù. Àå³»¿¡¼ ´ãÁó»ê°ú °áÇÕÇÏ¿© ´ãÁó»êÀÇ Àå°ü°£³» ¼øÈ¯À» ¾ïÁ¦ÇÏ¿© ´ëº¯À¸·Î ´ãÁó»êÀÇ ¹è¼³ÀÌ Áõ°¡ÇÏ¿© °£¼¼Æ÷³» ÄÝ·¹½ºÅ×·ÑÀ» °¨¼Ò½ÃŰ´Â ±âÀüÀ¸·Î ¾ÈÀüÇÑ ¹Ý¸é, À§ÀåÀå¾Ö(¿À½É, º¹ºÎÆØ¸¸, °¡½º Âü, º¯ºñ, ¼ÒȺҷ®)µîÀÌ ½ÉÇØ ÃÖ±Ù °ÅÀÇ »ç¿ëµÇÁö ¾Ê´Â´Ù. ¹Ý¸é, ÃÖ±Ù ¼Ò¾Æ¿¡¼ LDLÄÝ·¹½ºÅ×·ÑÀ» ³·Ãß´Â 1 Â÷ ¼±ÅÃÁ¦·Î¼ HMG CoA reductase inhibitor(StatinsÁ¦)¸¦ »ç¿ëÇÑ´Ù. HMG CoA reductase inhibitor´Â HMG CoA reductase¸¦ ¾ïÁ¦ÇØ °£¼¼Æ÷³» ÄÝ·¹½ºÅ×·Ñ ÇÕ¼ºÀ» ¾ïÁ¦Çϰí LDL ¼ö¿ëü¸¦ Áõ°¡½ÃÄÑ LDL, VLDL remnant ÀÇ Ç÷ÀåÁ¦°Å¸¦ Áõ°¡½Ã۸ç, Ç÷°ü¿¡ ´ëÇÑ Ç׿°Áõ ÀÛ¿ë ¹× Ç× Ç÷Àü ÀÛ¿ë, µ¿¸Æ³»ÇǼ¼Æ÷ È£ÀüÀÛ¿ë µîÀÌ ÀÖ´Ù. º¸Åë ÇÏ·ç 10mgÀ¸·Î ½ÃÀÛÇØ 6ÁÖÈÄ LDL<160mg/dl µÉ ¶§±îÁö Áõ·®Çϰí LDL<130mg/dlÀÌ µÇ¸é °¨·®ÇÑ´Ù. »çÃá±â Àü ÃÖ´ë·®Àº 40mg/D, »çÃá±â ÈÄ ÃÖ´ë·® 80mg/D Á¤µµÀÌ´Ù. ºÎÀÛ¿ëÀ¸·Î À§Àå°ü°è ºÒÆíÁõ»ó, µÎÅë, ¼ö¸éÀå¾Ö, Çǰï, Ⱦ¹®±Ù ºÐÇØ, °£È¿¼Ò »ó½ÂÀÌ ÀÖÀ» ¼ö ÀÖÁö¸¸ ½ÇÁ¦ ¸Å¿ì µå¹°´Ù. Cyto p450¿¡¼ ´ë»çµÇ¹Ç·Î ÀÌ systemÀ» ¾ïÁ¦ÇÏ´Â ¾à(erythromycin, antifungal agent)À» »ç¿ëÇÏ´Â °æ¿ì ÁÖÀÇÇÑ´Ù. Åõ¾à 4-6ÁÖ ÈÄ ¹× 3°³¿ù °£°Ý Lipid, OT/PT, ÇÊ¿ä½Ã CK¸¦ °Ë»çÇÏ¿© OT/PT 3¹è ÀÌ»ó, CK 10¹è ÀÌ»ó Áõ°¡½Ã ¾àÀ» º¯°æÇϸç ÁöÁú ³óµµ ¸ñÇ¥ ´Þ¼º ÈÄ Ã¹ 1³âÀº 2-3°³¿ù °£°ÝÀ¸·Î ´ÙÀ½ÇØ´Â 4-6°³¿ù °£°ÝÀ¸·Î °Ë»çÇÑ´Ù. ÃÖ±Ù, statin ¸¸À¸·Î LDLÄÝ·¹½ºÅ×·ÑÀÌ ³·¾ÆÁöÁö ¾Ê´Â °æ¿ì Àå¿¡¼ ÄÝ·¹½ºÅ×·Ñ Èí¼ö¸¦ ¾ïÁ¦ÇÏ´Â Ezetamibe°è Ä¡·áÁ¦°¡ ¼Ò¾Æ¿¡¼µµ ¿¬±¸Áß¿¡ ÀÖ´Ù.
|
| ¾à¹° |
±âÀü |
´ë»ó |
½ÃÀÛ¿ë·® |
| HMG CoA reductase inhibitors (statins) |
¡é Cholesterol and VLDL synthesis |
Elevated LDL |
5-80 mg qhs |
|
¡è Hepatic LDL receptors |
|
|
| Bile acid sequestrants: |
¡è Bile and excretion |
Elevated LDL |
|
| Cholestyramine |
|
|
4-32 g daily |
| Colestipol |
|
|
5-40 g daily |
| Nicotinic acid |
¡é Hepatic VLDL synthesis |
Elevated LDL |
100-2,000 mg tid |
|
|
Elevated TG |
|
| Fibric acid derivitives: |
¡è LPL |
Elevated TG |
600 mg bid |
| Gemfibrozil |
¡é VLDL |
|
|
| Fish oils |
¡é VLDL production |
Elevated TG |
3-10 g daily |
| Cholesterol absorption inhibitors: |
|
|
|
| Ezetamibe |
¡é Intestinal absorption cholesterol |
Elevated LDL |
10 mg daily | |
| | |